SYNERGY(SZ:300636) Ge Long Hui·2025-09-16 08:45Core Viewpoint - The company, Tonghe Pharmaceutical, has received a revised Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for its raw material drug Ticagrelor, which will enhance its supply capacity in the European market starting from September 12, 2025 [1] Group 1 - The revised CEP was issued due to the addition of a new production workshop by the company [1] - Ticagrelor is a novel, selective small-molecule anticoagulant that blocks platelet activation, used for treating acute coronary syndrome patients to reduce the occurrence of thrombotic cardiovascular diseases [1] - The approval of the new production workshop signifies an improvement in the company's ability to supply Ticagrelor in the European market, positively impacting its international business expansion [1]